A vasopressin analogue in treatment of diabetes insipidus. Six children, 3 adolescents, and 3 adults with vasopressin-sensitive diabetes insipidus were treated with a vasopressin analogue, DDAVP (1-deamino-8-D-arginine vasopressin), at a daily dose ranging from 5 to 20 ,ug administered twice a day intranasally. The period of follow-up of these patients has been from 3 months to 1 year.
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DDAVP was effective in maintaining normal diuresis and normal urine concentration during both day and night. No local or vasopressor side effects were observed. Compared to other antidiuretic drugs, such as nasal pitressin powder, lysine-vasopressin nasal spray, or pitressin tannate injections, used previously by the patients, DDAVP proved to be superior in the control of the diabetes insipidus and in the subjective feeling of the patients.
It is concluded that DDAVP is the drug of choice in the treatment of vasopressinsensitive diabetes insipidus.
Good control of diabetes insipidus is especially important in children since, in addition to the interference with normal school attendance, social activities, and night rest, normal growth is disturbed by the imbalance in water and electrolyte metabolism. Up to now none of the drugs employed have proved satisfactory and some have caused troublesome side effects.
We report our experience with a new antidiuretic preparation, DDAVP (1-deamino-8-D-arginine vasopressin), a synthetic analogue of the natural human antidiuretic hormone. Its features are a lack of pressor activity and side effects, together with a prolonged antidiuretic action.
Subjects and methods
Twelve patients (7 females and 5 males) with diabetes insipidus were included in this study. 9 were children or adolescents (5 years 9 months to 18 years) and 3 were adults. 2 of the adult patients (aged 224 and 24 years) have been under our care since childhood, while the third, a 34-year-old patient with a pituitary tumour, was under the care of the Department of Neurosurgery.
The pertinent clinical data are summarized in Table I .
Received 13 November 1973. All patients had been proven to be vasopressin-sensitive and previously had been treated with nasal pitressin powder (PP) (Lilly), lysine-8-vasopressin nasal spray (LVP) (Sandoz), or intramuscular injections of pitressin tannate in oil (PTO), with varying success. Two of the patients treated with LVP nasal spray required the drug at least three to four times a day and had to get up at night to urinate. Because of its short effectiveness, LVP was abandoned by most patients.
Six patients had been treated with PP intranasally. They required the drug two to four times a day, and all complained of vasopressor effects and of local irritation of the hasal mucosa. 1 patient (Case 5) switched to therapy with injections of PTO for various periods of time until the sore nasal mucosa had recovered, then changed back to the nasal powder because the injections were too painful to endure for long. Another patient (Case 4) reduced the dosage of the powder and supplemented it with carbamazepine (Tegretol), preferring the less satisfactory control of the diabetes insipidus to the troublesome side effects of the powder when taken at a fully effective dosage.
Two of the younger patients (Cases 7 and 9) could be managed only with PTO injections, both requiring an injection every other day. Even so, satisfactory control was not achieved and both suffered from pronounced nocturnal enuresis. The older of the 2 (Case 9) was unable to attend school properly because of her intractable polyuria and polydipsia. 482
A vasopressin analogue in treatment of diabetes insipidus Two of the adult patients (Cases 10 and 11) could not stand the vasopressor and local side effects of the intranasal spray and therefore switched to therapy with PTO injections.
One patient (Case 1) presented a particularly difficult therapeutic problem. Initially, the diabetes insipidus responded well to each of the above preparations, but in each case there was a rapid decrease in effectiveness (within several days to several weeks), and finally a total lack of response. Trials with various combinations of the vasopressin preparations as well as with chlorothiazide all failed.
All the 12 patients in this study were eventually placed on DDAVP therapy, but because of the limitation in the supply of the drug at the beginning, the most difficult patients were the first to be started on it.
Data on the 24-hour urine volume and urine specific gravity were recorded for all patients both during the previous antidiuretic treatment and during treatment with DDAVP. Urine osmolality was also determined in most patients during both periods. In 4 patients all antidiuretic therapy was stopped for 24 to 48 hours before DDAVP therapy was started, so that data could also be obtained for the nontreatment period.
All patients were given DDAVP intranasally in a solution containing 100 ,ug/ml, administered by means of a graded nasal tube. There were no technical difficulties in teaching the patients to perform the insufflation by themselves, and only with the youngest patient (Case 7) did an older member of the family have to administer the drug.
The initial dose was 5 ,tg (0 05 ml) administered twice daily. The smallest effective dose was determined for each patient by gradually increasing the dosage until normalization was achieved, as measured by urine volume and concentration and daily fluid intake.
In evaluating the effectiveness of DDAVP, the patient's general well-being, school performance, and social activities were included. The necessity of keeping the drug at a low temperature was shown, since 2 patients reported a reduced effect when it was not refrigerated; the average room temperature in this country is high (26-30°C in summer).
Results

Discussion
Vasopressin preparations generally available have three major disadvantages, inconvenience of administration, vasopressor and local side effects, and short duration of effectiveness. Refractoriness to therapy and allergic reactions also develop in some patients (Mimica, Wegienka, and Forsham, 1968; Bronstein, DeFelice, and Long, 1969; Laron, 1969; Lawrence, Hsu, and Lichtenstein, 1972) .
Other drugs with antidiuretic properties, such as thiazides (Lant and Wilson, 1971) , carbamazepine (Tegretol) (Delzant, Sebaoun, and Krivitzky, 1971; Stoll, Largier, and Tonz, 1972) , clofibrate (De Gennes et al., 1970) , and chlorpropamide (Kumar, Sutow, and Cole, 1969; Ehrlich and Kooh, 1970; Reimold, 1970) , have been tested with varying results. Largely unsatisfactory results as well as unpleasant side effects have been reported (Pinto and Stoppoloni, 1970) .
Our study confirms the findings reported by others (Vavra et al., 1968; Arner, 1971, 1972; Aronson et al., 1973; Edwards et al., 1973) that DDAVP lacks the disadvantages of the older vasopressin preparations: it is convenient to administer, there are no undesirable vasopressor or local side effects, and the duration of its effect is long enough (10 to 12 hours) to permit the patient to undertake normal activities. These qualities of DDAVP are ascribed to the differences in its chemical structure compared to natural human vasopressin, i.e. the deamination of hemicystine in position 1 and the presence of a D-arginine in position 8. It is believed that these structural changes increase the antidiuretic over the vasopressor effect and are responsible for the prolonged antidiuretic action, partly by delaying enzymatic degradation in the peripheral tissues (Aronson et al., 1973) .
Since submitting this paper, Nash (1973) has reported the case of a child of 10 years successfully treated with DDAVP.
We conclude that DDAVP is the drug of choice, giving satisfactory control of the symptoms of diabetes insipidus with practically no discomfort, and making possible a normal life. 
